<DOC>
	<DOCNO>NCT02733445</DOCNO>
	<brief_summary>The purpose study determine often likely patient develop Type 2 Diabetes high cholesterol/lipids receive dasatinib nilotinib therapy Chronic Myelogenous Leukemia ( CML ) .</brief_summary>
	<brief_title>Metabolic Outcomes Patients Receiving Tyrosine Kinase Inhibitor ( TKI ) Therapy With Dasatinib Nilotinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>18 year age old At least 1 prescription nilotinib dasatinib 7/1/200612/31/2014 Continuously enrol health plan throughout study period At least 2 diagnosis code CML least 30 day apart document medical insurance claim patient documented diagnosis diabetes medical claim receive medication diabetes receive dasatinib nilotinib patient document diagnosis high cholesterol/lipids medical claim receive medication high cholesterol/lipids receive dasatinib nilotinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>